

Journal of Hepatology

E-submissions and author instructions:
<http://mc.manuscriptcentral.com/jhep>

Contents: Volume 50 · Issue 2 · February 2009

EASL Clinical Practice Guidelines

- 227 EASL Clinical Practice Guidelines: Management of chronic hepatitis B European Association for the Study of the Liver (EASL), Switzerland

EASL News

- 243 EASL Clinical Practice Guidelines J.-M. Pawlotsky (France)

Editorials

- 244 Anti-HCV core antibody: A potential new marker of occult and otherwise serologically silent HCV infection T.I. Michalak, T.N.Q. Pham (Canada)
- 247 Is family history of liver cancer a risk factor for hepatocellular carcinoma? M.L. Volk, A.S.F. Lok (USA)
- 249 Iron in NASH, chronic liver diseases and HCC: How much iron is too much? A. Pietrangelo (Italy)
- 252 HBV protein as a double-barrel shot-gun targets epigenetic landscape in liver cancer Z. Herceg, A. Paliwal (France)

Original Articles

Viral Hepatitis

- 256 Identification of serologically silent occult hepatitis C virus infection by detecting immunoglobulin G antibody to a dominant HCV core peptide epitope J.A. Quiroga, I. Castillo, S. Llorente, J. Bartolomé, G. Barril, V. Carreño (Spain)
- Human Study* *See Editorial, pages 244–246*
- 264 Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan S.-C. Mu, Y.-M. Lin, G.-M. Jow, B.-F. Chen (Taiwan)
- Human Study*
- 273 The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: A longitudinal analysis Z.-L. Fang, C.A. Sabin, B.-Q. Dong, S.-C. Wei, Q.-Y. Chen, K.-X. Fang, J.-Y. Yang, X.-Y. Wang, T.J. Harrison (UK, PR China)
- Human Study*
- 281 The role of HBV genotype, core promoter and precore mutations in advanced liver disease in renal transplant recipients M.-C. Tsai, C.-H. Chen, C.-M. Lee, Y.-T. Chen, Y.-S. Chien, C.-H. Hung, J.-H. Wang, S.-N. Lu, Y.-H. Yen, C.-S. Changchien, T.-H. Hu (Taiwan)
- Human Study*



- 289 Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy

Human Study

D. Shouval, C.-L. Lai, T.-T. Chang, H. Cheinquer, P. Martin, G. Carosi, S. Han, S. Kaymakoglu, R. Tamez, J. Yang, D. Tenney, H. Brett-Smith (Israel, Hong Kong, Taiwan, Brazil, USA, Italy, Turkey)

Cirrhosis and its Complications

- 296 Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension

C. Tiani, E. Garcia-Pras, M. Mejias, A. de Gottardi, A. Berzigotti, J. Bosch, M. Fernandez (Spain)

Transplantation

- 306 Outcome after wait-listing for emergency liver transplantation in acute liver failure: A single centre experience

W. Bernal, T.J.S. Cross, G. Auzinger, E. Sizer, M.A. Heneghan, M. Bowles, P. Muiesan, M. Rela, N. Heaton, J. Wendon, J.G. O'Grady (UK)

Human Study

- 314 Prospective study of natural killer cell phenotype in recurrent hepatitis C virus infection following liver transplantation

S. Varchetta, B. Oliviero, M.F. Donato, F. Agnelli, C. Rigamonti, E. Paudice, E. Arosio, M. Berra, G. Rossi, C. Tinelli, F.F. Fagnoni, M. Colombo, D. Mavilio, M.U. Mondelli (Italy)

Human Study

Liver Failure, Growth and Cancer

- 323 Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer

Q. Chang, Y. Zhang, K.J. Beezhold, D. Bhatia, H. Zhao, J. Chen, V. Castranova, X. Shi, F. Chen (USA, PR China)

- 334 The association of family history of liver cancer with hepatocellular carcinoma: A case-control study in the United States

M.M. Hassan, M.R. Spitz, M.B. Thomas, S.A. Curley, Y.Z. Patt, J.-N. Vauthey, K.Y. Glover, A. Kaseb, R.D. Lozano, A.S. El-Deeb, N.T. Nguyen, S.H. Wei, W. Chan, J.L. Abbruzzese, D. Li (USA)

Human Study

See Editorial, pages 247–248

- 342 High-fat nutrition reduces hepatic damage following exposure to bacterial DNA and hemorrhagic shock

M.D.P. Luyer, J.P.M. Derikx, R. Beyaert, M. Hadfoune, T.H. van Kuppevelt, C.H.C. Dejong, E. Heineman, W.A. Buurman, J.W.M. Greve (The Netherlands, Belgium)

- 351 Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis

P. Sorrentino, S. D'Angelo, U. Ferbo, P. Micheli, A. Bracigliano, R. Vecchione (Italy)

Human Study

See Editorial, pages 249–251

- 358 The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma

L. Chen, H.-X. Yan, W. Yang, L. Hu, L.-X. Yu, Q. Liu, L. Li, D.-D. Huang, J. Ding, F. Shen, W.-P. Zhou, M.-C. Wu, H.-Y. Wang (PR China)

Molecular and Cell Biology

- 370 A functional variation in *CHI3L1* is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection

M.-L. Berres, S. Papen, K. Pauels, P. Schmitz, M.M. Zaldivar, C. Hellerbrand, T. Mueller, T. Berg, R. Weiskirchen, C. Trautwein, H.E. Wasmuth (Germany)

Human Study

- 377 Epigenetic modification induced by hepatitis B virus X protein via interaction with *de novo* DNA methyltransferase DNMT3A

D.-L. Zheng, L. Zhang, N. Cheng, X. Xu, Q. Deng, X.-M. Teng, K.-S. Wang, X. Zhang, J. Huang, Z.-G. Han (China)

See Editorial, pages 252–255

Cholestasis and Autoimmune Liver Disease

- 388 Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients

Human Study

M. Werner, S. Almer, H. Prytz, S. Lindgren, S. Wallerstedt, E. Björnsson, A. Bergquist, H. Sandberg-Gertzén, R. Hultcrantz, P. Sangfelt, O. Weiland, A. Danielsson (Sweden)

Genetic and Metabolic Liver Disease

- 394 Pro-hepcidin is unable to degrade the iron exporter ferroportin unless matured by a furin-dependent process

B. Gagliardo, N. Kubat, A. Faye, M. Jaouen, B. Durel, J.-C. Deschemin, F. Canonne-Hergaux, M.-A. Sari, S. Vaulont (France)

Reviews

- 402 Ribavirin: Current role in the optimal clinical management of chronic hepatitis C

K.R. Reddy, D.R. Nelson, S. Zeuzem (USA, Germany)

- 412 Treatment failure in hepatitis C: Mechanisms of non-response

A.W. Tai, R.T. Chung (USA)

Letters to the Editor

- 421 HCV and fat: Something is missing

E.G. Giannini, V. Savarino (Italy)

- 422 Hepatitis C viremia and serum lipid levels: A clue from an epidemiology study

C.-Y. Dai, W.-L. Chuang, C.-K. Ho, M.-L. Yu (Taiwan)

- 423 Interpreting liver stiffness in the cirrhotic range

P. Bioulac-Sage, T. Couffignal, J. Foucher, C.P. Balabaud (France)

- 424 Interpreting liver stiffness in the cirrhotic range: What are we measuring?

L. Castéra, X. Forns, A. Alberti (France, Spain, Italy)

Case Reports

- 426 Acute hepatitis B in a healthcare worker: A case report of genuine vaccination failure

H.J. Boot, L.A. van der Waaij, J. Schirm, C.G.M. Kallenberg, J. van Steenberghe, B. Wolters (The Netherlands)

- 432 Complete cure of HBV-HDV co-infection after 24 weeks of combination therapy with pegylated interferon and ribavirin in a patient co-infected with HBV/HCV/HDV/HIV

J. Gozlan, K. Lacombe, E. Gault, G. Raguin, P.-M. Girard (France)

Journal Club

- 435 Chronic hepatitis E in the immunosuppressed: A new source of trouble?

F. Bihl, F. Negro (Switzerland)

Corrigendum

- 438 Corrigendum to "Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive Non-Hodgkin's lymphoma" [J Hepatol 49 (2008) 557-563]

V. La Mura, A. De Renzo, F. Perna, D. D'Agostino, M. Masarone, M. Romano, S. Bruno, R. Torella, M. Persico (Italy)

Announcements

439

Cover Figure MicroRNA in human intrahepatic cholangiocarcinoma. Mcl-1 expression, a member of Bcl-2 gene family regarded as an apoptosis suppressor, by immunohistological analysis, was significantly higher in intrahepatic cholangiocarcinoma (ICC) (left panel) than in paired non-ICC adjacent normal tissues (middle panel) as well as normal liver (right panel), with an inverse correlation with the expression of mir-320 (see article by Chen et al on page 358)